Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions

Original reporting
Published Aug 29, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 3:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands — source image
Decision brief

The 30-second read

$VMDNeutralMed
01

Why it matters

The guidance and acquisition updates provide fresh insight into growth trajectory and cash‑flow outlook.

02

Market read

First report of 2026 guidance and recent acquisitions offers actionable data for investors in VMD and sector peers.

03

What to watch

Potential impact of GLP‑1 drugs on sleep‑therapy demand and future debt‑financed acquisitions.

Relevance 8/10Novelty 8/10Timing: guidance released today

Background

Viemed Healthcare provides home‑based respiratory therapy, recently expanded via acquisitions and new product lines.

Company-level read

Ticker impact

$VMDNeutralHigh confidence
Context

Company issued 2026 revenue guidance of $317M and low‑20% growth, plus disclosed recent acquisitions and capital allocation plans.

Expected impact

Potential modest upside if guidance beats market expectations; downside risk if growth slows.

Evidence & confidence

First disclosure of full‑year guidance and acquisition activity provides fresh data for valuation models.

Market effects

Highlights growth in home respiratory therapy and sleep‑therapy markets, may benefit peers.

Focus on U.S. home‑care services; limited broader regional effect.

Limited to U.S. healthcare equipment sector.

Counterpoint

Guidance may be overly optimistic given capital intensity and margin pressure from new lines.

Key entities

  • Todd Zehnder

    Chief Operating Officer, provided guidance and capital allocation comments.

  • Lehan's

    Recent acquisition adding respiratory and maternal health capabilities.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

Med

Viemed Healthcare Announces New Share Repurchase Program of Up to 5% of Shares Outstanding – Minichart

Viemed Healthcare reported Q2 2026 revenue of $78.1M (up 24% Y-o-Y) and Adjusted EBITDA of $13.7M. The company announced a new share repurchase program for up to 5% of outstanding shares, following a strong first half with 680,802 shares repurchased. Full-year 2026 guidance is $314M-$320M in revenue and $64M-$68M in Adjusted EBITDA. The company has a strong balance sheet with $10.7M in cash and no net debt as of June 30, 2026.